Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04362501 · ClinicalTrials.gov registry record · Phase 2

Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

A Phase 2 study of Chronic Sinusitis, sponsored by Johns Hopkins University.

Completed
Registry status
Phase 2
Development phase
33
Enrollment target
1
Study location

NCT04362501 is a Phase 2 study of Chronic Sinusitis that has completed, run by Johns Hopkins University. The registered enrollment target is 33 participants, below the 192-participant average among 9 other Chronic Sinusitis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04362501, a Phase 2 study of Chronic Sinusitis, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
Phase 2
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

The overarching objective of this study is to determine the clinical effectiveness of dupilumab for the treatment of CRS that includes several potential disease endotypes with the exclusion of the nasal polyp cluster that has previously been determined. The additional information gained from secondary and exploratory outcomes will help provide important insight for applied research studies and may also provide practical guidance to clinicians on how to select patients for treatment.

Conditions Studied

Interventions

  • DRUG placebo
  • BIOLOGICAL dupilumab

Study Locations (1)

Maryland

  • Johns Hopkins University School of Medicine - Baltimore

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2020-10-15
Est. Completion 2025-09-30
Phase Phase 2

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT04362501

The ClinicalTrials.gov registry entry for NCT04362501 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 9 other Chronic Sinusitis trials with a reported enrollment target (83% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Sinusitis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT04362501 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT04362501 about?

NCT04362501 is a clinical study titled "Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)". The overarching objective of this study is to determine the clinical effectiveness of dupilumab for the treatment of CRS that includes several potential disease endotypes with the exclusion of the nasal polyp cluster that has previously been determined. The additional information gained from seconda...

What is the current status of trial NCT04362501?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2020-10-15. Estimated completion is 2025-09-30.

What conditions does trial NCT04362501 study?

This clinical trial studies the following conditions: Chronic Sinusitis.

What interventions are being tested in trial NCT04362501?

The interventions under investigation include: placebo (DRUG), dupilumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT04362501?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04362501 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Sinusitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.